LEADER trial data included in Novo Nordisks Saxenda in Europe
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
New test may turn AZ’s Lynparza into precision drug for prostate cancer
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
Sanofi’s and Regeneron’s diabetes drug testing shows positive results
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.
J&J receives final EC approval to acquire Actelion
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.
Vertex Pharmaceuticals welcomes new independent board member
Vertex Pharmaceuticals has appointed Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors.
Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management
Lyfebulb and Novo Nordisk have join again to support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes – and ultimately our societies.
Allergan acquires Keller Medical, a medical device company
Allergan’s wholly-owned subsidiary, Allergan Sales LLC has acquired Keller Medical, a privately held medical device company and developer of the Keller Funnel.
Celgene Corporation and Agios Pharmaceuticals report first results from acute myeloid leukemia study
Celgene Corporation and Agios Pharmaceuticals have reported new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation.
Novo Nordisk to sell its haemophilia B drug in EU
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
